Fintel reports that on November 4, 2025, Stephens & Co. initiated coverage of Twist Bioscience (NasdaqGS:TWST) with a ...

TD Cowen analyst Tyler Van Buren initiated coverage on MBX Biosciences, Inc. (NASDAQ: MBX) with a Buy rating. MBX Biosciences ...

Twist Bioscience is advancing synthetic DNA manufacturing with innovation but remains at the lower end of its 52-week range.

Twist Bioscience specializes in synthetic DNA production, providing gene fragments, next generation sequencing (NGS) tools, and antibody discovery platforms to research, diagnostic, pharmaceutical, ...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL).

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Detailed price information for Twist Bioscience Corp (TWST-Q) from The Globe and Mail including charting and trades.

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) ("Twist" or the "Company"), ...

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the ...